Abstract
Background: Lung cancer is the leading cause of cancer-associated mortality in the world. Traditional cancer therapies prolong the life expectancy of patients but often suffer from adverse reactions. Photodynamic Therapy (PDT) has been recommended as a treatment option for lung cancer in several countries, due to its non-invasive procedures, high selectivity and weak side effects.
Objective: We have designed and synthesized a biotin receptor-targeted silicon phthalocyanine (IV) (compound 1) which showed a good therapeutic effect on biotin receptor-positive tumors. Since the overexpression of Biotin Receptor (BR) is also present in human lung cancer cells (A549), we explored the therapeutic properties of compound 1 on A549 xenograft tumor models.
Methods: The selectivity of compound 1 toward A549 cells was studied with a fluorescence microscope and IVIS Spectrum Imaging System. The cytotoxicity was measured using the MTT assay. In vivo anti-tumor activity was investigated on the nude mice bearing A549 xenografts.
Results: In vitro assays proved that compound 1 could selectively accumulate in A549 cells via the BR-mediated internalization. In vivo imaging and distribution experiments showed that compound 1 could selectively accumulate in tumor tissues of tumor-bearing mice. After 16 days of the treatment, the volumes of tumor in the PDT group were obviously smaller than that in other groups.
Conclusion: This study demonstrates that compound 1 is a promising photosensitizer and has broad application prospects in clinical PDT of lung cancers.
Keywords: Lung cancer, Photodynamic Therapy (PDT), silicon phthalocyanine, BR-mediated, photosensitizer, singlet oxygen.
Graphical Abstract
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[http://dx.doi.org/10.1007/s00520-018-4338-3] [PMID: 29980906]
[http://dx.doi.org/10.1021/acsami.9b02695] [PMID: 30901194]
[http://dx.doi.org/10.1080/10717544.2019.1606363 ] [PMID: 31033359]
[http://dx.doi.org/10.1016/j.jddst.2019.01.024]
[http://dx.doi.org/10.1021/acs.bioconjchem.9b00231] [PMID: 31023011]
[http://dx.doi.org/10.1016/S1011-1344(96)07372-1] [PMID: 9002261]
[http://dx.doi.org/10.1016/j.msec.2017.03.124] [PMID: 28482576]
[http://dx.doi.org/10.1021/acs.jafc.8b04627] [PMID: 30339011]
[http://dx.doi.org/10.1016/j.clon.2018.01.018] [PMID: 29459100]
[http://dx.doi.org/10.1016/j.athoracsur.2018.08.053 ] [PMID: 30316853]
[http://dx.doi.org/10.3322/caac.20114] [PMID: 21617154]
[http://dx.doi.org/10.1038/nrc1070] [PMID: 12724735]
[http://dx.doi.org/10.1039/cs9952400019]
[http://dx.doi.org/10.1634/theoncologist.11-9-1034 ] [PMID: 17030646]
[http://dx.doi.org/10.1007/s10495-010-0479-7] [PMID: 20221698]
[http://dx.doi.org/10.1016/j.ejmech.2018.05.039] [PMID: 29852329]
[http://dx.doi.org/10.1016/j.actbio.2014.06.026] [PMID: 24969665]
[http://dx.doi.org/10.2174/1389200217666151120165404 ] [PMID: 26593738]
[http://dx.doi.org/10.1177/153303460500400308] [PMID: 15896084]
[http://dx.doi.org/10.1111/phpp.12489] [PMID: 31155747]
[http://dx.doi.org/10.2174/1389201043376805] [PMID: 15320770]
[http://dx.doi.org/10.1002/lsm.20354] [PMID: 16788932]
[http://dx.doi.org/10.1016/j.pdpdt.2011.03.342] [PMID: 21864796]
[PMID: 26646726]
[http://dx.doi.org/10.1016/j.clindermatol.2005.10.027 ] [PMID: 16427502]
[http://dx.doi.org/10.1039/B915149B] [PMID: 20694259]
[http://dx.doi.org/10.7150/thno.16183] [PMID: 27877247]
[http://dx.doi.org/10.1016/j.jphotobiol.2018.09.001 ] [PMID: 30453160]
[http://dx.doi.org/10.1016/j.ejmech.2013.11.012] [PMID: 24308999]
[http://dx.doi.org/10.1016/j.ijpharm.2018.12.069] [PMID: 30599231]
[http://dx.doi.org/10.1371/journal.pone.0079566] [PMID: 24223971]
[http://dx.doi.org/10.1021/jacs.8b08658] [PMID: 30362735]
[http://dx.doi.org/10.1080/10717544.2018.1435751 ] [PMID: 29461122]
[http://dx.doi.org/10.2174/138920106778521541] [PMID: 17076648]
[PMID: 21498711]
[http://dx.doi.org/10.1016/j.biomaterials.2016.01.009 ] [PMID: 26803408]
[http://dx.doi.org/10.1039/C6RA07480D]